In a prior study by the same group they found that anti-PD-1 therapy produced an objective response in 20–25% of patients with treatment-resistant NSCLC, renal cell carcinoma and melanoma and that PD-L1 expression by tumor cells seemed to be associated with a response to therapy [45]. Here, CD274 is linked to melanoma.